Series A: Valuation Price Per Share



SPA price per share fixes post-money valuation, Original Issue Price, and Conversion Price at once, tying 409A compliance and anti-dilution terms together.

NVCA Critical Commercial Issues: Valuation and Price Per Share

The price per share recorded in a Series A Stock Purchase Agreement is not simply a number that founders and investors agree upon and move past. It is the legal and financial anchor for every economic right that follows, and practitioners who treat it as a ministerial matter rather than a strategic one underserve their clients.

The purchase price per share in the NVCA Stock Purchase Agreement simultaneously establishes the post-money valuation of the company, defines the Original Issue Price used in liquidation preference calculations under the Certificate of Incorporation, and sets the initial Conversion Price from which any anti-dilution adjustment begins. Those three functions are codified in separate documents that cross-reference the SPA price, creating an interdependence that makes even a small pricing error consequential across the entire financing structure.

The pre-money valuation embedded in the SPA price is not the number investors and founders typically discuss in term sheet negotiations. Founders frequently confuse the stated pre-money valuation with the economic pre-money valuation after accounting for the option pool. Almost every term sheet for a venture financing includes a provision expanding the company’s equity compensation plan to a specified percentage of the post-money fully diluted capitalization, and that expansion is computed on a pre-money basis, meaning the new option shares reduce the founders’ post-money ownership without reducing the stated pre-money valuation. A company valued at $15 million pre-money on a stated basis may carry an effective pre-money valuation to founders of $12 million or less after a two-percentage-point option pool top-up at a cap table of 15 million shares.

The SPA price must also be consistent with the most recent 409A valuation of the company’s common stock. Section 409A of the Internal Revenue Code requires that stock options be granted with an exercise price at or above the fair market value of the underlying common stock on the grant date, and failure to comply results in immediate income recognition, a 20 percent penalty tax, and applicable interest for the option holder. When investors pay $5.00 per share for Series A preferred stock, the 409A valuation must account for the liquidation preference and other superior rights of the preferred to arrive at a common stock fair value that is typically 25 to 40 percent lower than the preferred price. A company that closes a Series A without updating its 409A, or that grants options after closing at the old common stock price, runs a meaningful Section 409A compliance risk.

The October 2025 NVCA updates formalized tranched financing structures in the SPA, and that change adds a dimension to the valuation conversation that did not exist under prior iterations. In a tranched financing, the parties must agree at the outset whether the price for subsequent tranche closings is fixed at the initial tranche price or is subject to reset based on the pre-money valuation at the time of the subsequent closing. A fixed price provides founders with certainty about the dilution from the full commitment, while a floating price protects investors from the risk that the company’s condition deteriorates between closings. From a legal drafting standpoint, the milestone definitions must be specific enough to make the tranche pricing determination objective and auditable, because ambiguity about whether a milestone has been achieved will almost in fact produce a dispute about what price governs the subsequent issuance.

The board of directors’ obligation when approving the SPA price is meaningful and enforceable. The board must approve the price as fair to the company and all of its stockholders, and that approval is subject to challenge under the business judgment rule. Because venture investors typically hold board seats, or at minimum informal influence over the board, any transaction in which an investor-affiliated director votes to approve a price that appears favorable to investors at the expense of common stockholders may be subject to entire fairness review. This analysis is particularly relevant in insider-led rounds where existing investors set the price without competitive tension from new investors.

Pricing in the secondary market has added complexity to the valuation analysis since 2023. As IPO timelines have extended and companies have remained private longer, founders and employees have sought liquidity through secondary transactions, and institutional buyers have purchased common stock positions at prices that sometimes reflect very different valuation assumptions than the most recent preferred round price. A secondary common stock transaction that occurs at a price implying a post-money valuation higher than the last preferred round price creates a tension with the 409A common stock fair value used for option grants: if the common is being sold at prices implying a per-share value of $4.00, it is difficult to defend a 409A that values the common at $2.00 for option pricing purposes.

The one issue that remains most contested in current market practice is the treatment of price adjustments in convertible note and SAFE financings that convert into the priced round. Most SAFEs and convertible notes include a valuation cap and a discount, both of which produce a lower effective conversion price than the SPA price. The resulting additional shares issued to SAFE and note holders dilute the common stockholders and reduce the effective pre-money valuation received by them below the stated term sheet valuation. Practitioners should model the fully diluted post-money cap table before any financing to ensure that founders and common holders understand the actual dilution they are incurring after all instruments convert.

Interested in analysis about the relationship between corporate law, securities regulation, tech, artificial intelligence, public policy and the law? Check out my Substack channel. https://theinnovationattorney.substack.com/